Paediatric antiretroviral update

Paediatric antiretroviral update

No abstract available.

Bibliographic Details
Main Authors:	Gillian Sorour, Nosisa Sipambo, Moherndran Archary
Format:	Article
Language:	English
Published:	AOSIS 2023-07-01
Series:	Southern African Journal of HIV Medicine
Subjects:	paediatric pediatric art formulations dolutegravir dolutegravir-based regimen children infants hiv
Online Access:	https://sajhivmed.org.za/index.php/hivmed/article/view/1506

Similar Items

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal
by: Sibongiseni Malinga, et al.
Published: (2023-05-01)

Optimised paediatric antiretroviral treatment to achieve the 95-95-95 goals
by: Moherndran Archary, et al.
Published: (2021-09-01)

Prevalence of and Factors Associated with Hypertension Among Adults on Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross Sectional Study
by: Kasoma Mutebi R, et al.
Published: (2023-04-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir
by: Erik Belfrage, et al.
Published: (2023-07-01)

Virological Non-Suppression, Non-Adherence and the Associated Factors Among People Living with HIV on Dolutegravir-Based Regimens: A Retrospective Cohort Study
by: Kabiibi F, et al.
Published: (2024-03-01)

ANÁLISE DO PERFIL EPIDEMIOLÓGICO E DA EFICÁCIA DO USO DA TERAPIA DUPLA EM PACIENTES HIV DO AMBULATÓRIO DE INFECTOLOGIA DO HOSPITAL SANTA CASA DE MISERICÓRDIA DE VITÓRIA/ES
by: Victória Kelbert Lima, et al.
Published: (2023-10-01)

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
by: Perez Nicholas Ochanda, et al.
Published: (2022-06-01)

Evaluation of the Side Effects of Antiretroviral Treatment
by: Sedef BAŞGÖNÜL, et al.
Published: (2018-12-01)

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
by: Arturo Ciccullo, et al.
Published: (2022-01-01)

Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda
by: Irene Nakatudde, et al.
Published: (2024-04-01)

Searching for a long-acting injectable formulation for the antiretroviral dolutegravir
by: Anderson Aparecido de Marchi, et al.
Published: (2019-12-01)

Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
by: Lisa Jane Frigati, et al.
Published: (2022-03-01)

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda
by: Yussif Alhassan, et al.
Published: (2020-12-01)

Addressing Pediatric HIV Pretreatment Drug Resistance and Virologic Failure in Sub-Saharan Africa: A Cost-Effectiveness Analysis of Diagnostic-Based Strategies in Children ≥3 Years Old
by: Mutita Siriruchatanon, et al.
Published: (2021-03-01)

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report
by: Sheila Chiesi, et al.
Published: (2019-07-01)

DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain
by: Sergio Sequera-Arquelladas, et al.
Published: (2024-02-01)

A case report of untreatable HIV infection in Harare, Zimbabwe
by: Cleophas Chimbetete, et al.
Published: (2019-06-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
by: Adelline Twimukye, et al.
Published: (2021-11-01)

SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV NA BAHIA: DADOS DE VIDA REAL
by: Thiago Pinho Cordeiro Araújo, et al.
Published: (2023-10-01)

RESISTÊNCIA AO DOLUTEGRAVIR EM UM CASO DE TRANSMISSÃO VERTICAL
by: Clarissa Barros Madruga, et al.
Published: (2023-10-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study
by: Roberta Gagliardini, et al.
Published: (2022-03-01)

Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimenResearch in context
by: Roux-Cil Ferreira, et al.
Published: (2024-04-01)

Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study
by: Angella Namulindwa, et al.
Published: (2022-04-01)

MEDICINE AND THE LAW
by: A Bangalee, et al.
Published: (2022-10-01)

Suicidal overdose of dolutegravir: A case report
by: Rahul Daimari, et al.
Published: (2018-06-01)

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
by: Tinei Shamu, et al.
Published: (2024-02-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial
by: Linda Namutebi Barlow‐Mosha, et al.
Published: (2023-09-01)

ALTERAÇÃO NO ÍNDICE DE MASSA CORPÓREA (IMC) APÓS SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV ATENDIDOS EM UM SERVIÇO ESPECIALIZADO DE SALVADOR, BAHIA
by: Thiago Pinho Cordeiro Araújo, et al.
Published: (2023-10-01)

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL
by: Ana Caroline Coutinho Iglessias, et al.
Published: (2023-10-01)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
by: Ying Zhao, et al.
Published: (2022-09-01)

Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex
by: Xiaoqin Le, et al.
Published: (2022-03-01)

Two cases of neural tube defects with dolutegravir use at conception in south Brazil
by: Regis Kreitchmann, et al.
Published: (2021-03-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Sex differences in hypertension among people living with HIV after initiation of antiretroviral therapy
by: Sepiso K. Masenga, et al.
Published: (2022-11-01)

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen
by: Ahmed Badat, et al.
Published: (2022-03-01)